| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Microbial Metabolite
O-Desmethylangolensin targets cancer cell proliferation and survival pathways. It exerts anticancer effects through the induction of cell cycle arrest and apoptosis. It inhibits the growth of HepG2 cells at higher doses and suppresses the proliferation of human breast cancer MCF-7 cells. It also has estrogenic activities. |
|---|---|
| ln Vitro |
Higher doses of O-Desmethylangolensin (O-DMA) (about 30% reduction at 75 μM) impede the development of HepG2 cells [2].
In vitro, O-Desmethylangolensin inhibits the growth of HepG2 cells with approximately 30% decrease at 75 µM. It suppresses the proliferation of human breast cancer MCF-7 cells by inducing apoptosis and promoting cell cycle arrest. It exhibits anticancer, anti-inflammatory, and antioxidant activities in various experimental models. |
| ln Vivo |
In vivo, O-Desmethylangolensin is a gut bacterial metabolite of daidzein. Its presence in individuals varies based on gut microbiota composition, influencing the health effects of soy consumption. It may play a role in reducing the risk of hormone-related cancers, cardiovascular diseases, and osteoporosis. Its estrogenic activities suggest potential effects on hormone-sensitive tissues.
|
| Enzyme Assay |
In vitro assays for O-Desmethylangolensin typically involve cell proliferation and apoptosis studies. Cancer cells (e.g., HepG2, MCF-7) are cultured and treated with O-DMA at concentrations ranging from 1-100 µM. Cell viability is assessed by MTT or SRB assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Cell cycle analysis is performed by flow cytometry.
|
| Cell Assay |
For in vitro cell assays, cancer cell lines (e.g., HepG2, MCF-7, Hep3B) are cultured in appropriate media and treated with O-Desmethylangolensin at various concentrations. Cell proliferation is measured by MTT or BrdU incorporation assays. Apoptosis is assessed by flow cytometry. Anti-inflammatory activity is evaluated by measuring cytokine production in stimulated immune cells. Antioxidant activity is assessed by ROS measurement.
|
| Animal Protocol |
For in vivo animal studies, O-Desmethylangolensin is typically administered to rodents via oral gavage in studies of isoflavone metabolism and health effects. The compound's effects on tumor growth are evaluated in xenograft models. Its estrogenic activities are assessed in hormone-sensitive tissues. Pharmacokinetic studies measure O-DMA levels in plasma and tissues by LC-MS/MS.
|
| ADME/Pharmacokinetics |
O-Desmethylangolensin (MW 258.27) has the molecular formula C15H14O4. It is a gut bacterial metabolite of the soy isoflavone daidzein. The compound is stable under recommended storage conditions. Its presence in individuals is influenced by gut microbiota composition. It is known for its potential health benefits, including antioxidant, anti-inflammatory, and estrogenic activities.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
O-Desmethylangiotensin (ODMA) exhibits antagonistic activity against androgen receptors and agonistic activity against estrogen receptors (ER)-α and ERβ. The structure of ODMA is somewhat similar to that of estrogen. (A15413) The compound is for research use only. No specific toxicity data are available. As a natural gut bacterial metabolite, it is expected to have low toxicity at physiological concentrations. However, its estrogenic activities suggest potential effects on hormone-sensitive tissues at higher doses. Standard laboratory safety precautions should be followed. |
| References |
|
| Additional Infomation |
O-Desmethylangoranin is a stilbene compound. O-Desmethylangoranin (ODMA) is a metabolite of the soy isoflavone daidzein in the gut bacteria of approximately 80-90% of the human population. Studies have shown that daidzein metabolic phenotypes are associated with health benefits, and that ODMA production is associated with certain phenotypes. Dietary factors associated with daidzein metabolic phenotypes are few. However, it is unclear why some (but not all) individuals have ODMA-producing bacteria. ODMA production is negatively correlated with age, height, weight, and body mass index. Furthermore, Asians are less likely to produce ODMA than Caucasians, and former smokers are more likely to produce ODMA than non-smokers. Researchers have attempted to identify bacteria involved in ODMA production and have identified several candidate bacteria, but these have not yet been definitively identified. ODMA production is correlated with the abundance of methanogens, suggesting that the metabolic fate of daidzein may be related to gut H(2) metabolism (A3192, A3193).
O-Desmethylangolensin (CAS# 21255-69-6) is a gut bacterial metabolite of the soy isoflavone daidzein. It has not been investigated in clinical trials nor approved as a therapeutic drug. The compound is used in research on cancer, inflammation, oxidative stress, and the health effects of soy consumption. It is a valuable tool for studying the role of gut microbiota in mediating the health benefits of dietary isoflavones. |
| Molecular Formula |
C15H14O4
|
|---|---|
| Molecular Weight |
258.27
|
| Exact Mass |
258.089
|
| CAS # |
21255-69-6
|
| PubChem CID |
89472
|
| Appearance |
White to off-white solid powder
|
| Density |
1.329g/cm3
|
| Boiling Point |
483.3ºC at 760mmHg
|
| Flash Point |
260.2ºC
|
| Vapour Pressure |
5.76E-10mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
2.789
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
309
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C1=CC=C(C=C1)O)C(=O)C2=C(C=C(C=C2)O)O
|
| InChi Key |
JDJPNKPFDDUBFV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14O4/c1-9(10-2-4-11(16)5-3-10)15(19)13-7-6-12(17)8-14(13)18/h2-9,16-18H,1H3
|
| Chemical Name |
1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)propan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 62.5 mg/mL (241.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8719 mL | 19.3596 mL | 38.7192 mL | |
| 5 mM | 0.7744 mL | 3.8719 mL | 7.7438 mL | |
| 10 mM | 0.3872 mL | 1.9360 mL | 3.8719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
